| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Harvest F Gu, Suad Efendic, Sofia Nordman, Claes-Göran Ostenson, Kerstin Brismar, Anthony J Brookes, Jonathan A Princ. Quantitative trait loci near the insulin-degrading enzyme (IDE) gene contribute to variation in plasma insulin levels. Diabetes. vol 53. issue 8. 2004-09-17. PMID:15277398. |
two recent studies presented genetic association data on ide and type 2 diabetes (one positive and the other negative), but neither explored the fundamental question of whether polymorphism in ide has a measurable influence on insulin levels in human populations. |
2004-09-17 |
2023-08-12 |
human |
| Harvest F Gu, Suad Efendic, Sofia Nordman, Claes-Göran Ostenson, Kerstin Brismar, Anthony J Brookes, Jonathan A Princ. Quantitative trait loci near the insulin-degrading enzyme (IDE) gene contribute to variation in plasma insulin levels. Diabetes. vol 53. issue 8. 2004-09-17. PMID:15277398. |
analyses based on haplotypic genotypes (diplotypes), constructed with snps that differentiate common extant haplotypes extending across ide, provided compelling evidence of association with fasting insulin levels (p = 0.0009), 2-h insulin levels (p = 0.0027), homeostasis model assessment of insulin resistance (p = 0.0001), and bmi (p = 0.0067), with effects exclusively evident in men. |
2004-09-17 |
2023-08-12 |
human |
| Harvest F Gu, Suad Efendic, Sofia Nordman, Claes-Göran Ostenson, Kerstin Brismar, Anthony J Brookes, Jonathan A Princ. Quantitative trait loci near the insulin-degrading enzyme (IDE) gene contribute to variation in plasma insulin levels. Diabetes. vol 53. issue 8. 2004-09-17. PMID:15277398. |
the strongest evidence for an effect of a single marker was obtained for rs2251101 (located near the 3' untranslated region of ide) on 2-h insulin levels (p = 0.000023). |
2004-09-17 |
2023-08-12 |
human |
| Harvest F Gu, Suad Efendic, Sofia Nordman, Claes-Göran Ostenson, Kerstin Brismar, Anthony J Brookes, Jonathan A Princ. Quantitative trait loci near the insulin-degrading enzyme (IDE) gene contribute to variation in plasma insulin levels. Diabetes. vol 53. issue 8. 2004-09-17. PMID:15277398. |
results indicate that polymorphism in/near ide contributes to a large proportion of variance in plasma insulin levels and correlated traits, but questions of sex specificity and allelic heterogeneity will need to be taken into consideration as the molecular basis of the observed phenotypic effects unfolds. |
2004-09-17 |
2023-08-12 |
human |
| Steven D Edlan. Insulin-degrading enzyme, apolipoprotein E, and Alzheimer's disease. Journal of molecular neuroscience : MN. vol 23. issue 3. 2004-08-26. PMID:15181249. |
insulin-degrading enzyme (ide) is a protease that degrades insulin and the beta-amyloid (abeta) peptide implicated in alzheimer's disease (ad). |
2004-08-26 |
2023-08-12 |
human |
| Steven D Edlan. Insulin-degrading enzyme, apolipoprotein E, and Alzheimer's disease. Journal of molecular neuroscience : MN. vol 23. issue 3. 2004-08-26. PMID:15181249. |
for example, insulin, a competitive inhibitor of ide activity toward abeta, may be elevated in non-epsilon4 cases. |
2004-08-26 |
2023-08-12 |
human |
| B A Van Tine, A J Patterson, J E Kudlo. Assignment of N-acetyl-D-glucosaminidase (Mgea5) to rat chromosome 1q5 by tyramide fluorescence in situ hybridization (T-FISH): synteny between rat, mouse and human with Insulin Degradation Enzyme (IDE). Cytogenetic and genome research. vol 103. issue 1-2. 2004-05-28. PMID:15008141. |
assignment of n-acetyl-d-glucosaminidase (mgea5) to rat chromosome 1q5 by tyramide fluorescence in situ hybridization (t-fish): synteny between rat, mouse and human with insulin degradation enzyme (ide). |
2004-05-28 |
2023-08-12 |
mouse |
| Tomo Saric, Dieter Müller, Hans-Joachim Seitz, Kresimir Paveli. Non-covalent interaction of ubiquitin with insulin-degrading enzyme. Molecular and cellular endocrinology. vol 204. issue 1-2. 2004-04-30. PMID:12850277. |
insulin-degrading enzyme (ide) is a metalloprotease implicated in insulin degradation and suggested to have a variety of additional functions, including the clearance of amyloid beta peptides of alzheimer's disease. |
2004-04-30 |
2023-08-12 |
mouse |
| Wesley Farris, Stefan Mansourian, Malcolm A Leissring, Elizabeth A Eckman, Lars Bertram, Christopher B Eckman, Rudolph E Tanzi, Dennis J Selko. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. The American journal of pathology. vol 164. issue 4. 2004-04-29. PMID:15039230. |
here, we show that naturally occurring ide missense mutations in a well-characterized rat model of type 2 diabetes mellitus (dm2) result in decreased catalytic efficiency and a significant approximately 15 to 30% deficit in the degradation of both insulin and abeta. |
2004-04-29 |
2023-08-12 |
mouse |
| Jonathan A Prince, Lars Feuk, Harvest F Gu, Boo Johansson, Margaret Gatz, Kaj Blennow, Anthony J Brooke. Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Human mutation. vol 22. issue 5. 2004-04-12. PMID:14517947. |
within the region, the gene for insulin degrading enzyme (ide) represents a notable biological candidate given that it degrades amyloid beta-protein (one of the major constituents of senile plaques) and the intracellular amyloid precursor protein (app) domain released by gamma-secretase processing. |
2004-04-12 |
2023-08-12 |
Not clear |
| Eun-Suk Song, Maria Aparecida Juliano, Luiz Juliano, Louis B Hers. Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development. The Journal of biological chemistry. vol 278. issue 50. 2004-01-15. PMID:14527953. |
the selective activation of ide toward amyloid beta peptide relative to insulin suggests the potential for development of compounds that increase ide activity toward amyloid beta peptide as a therapeutic intervention for the treatment of alzheimer's disease. |
2004-01-15 |
2023-08-12 |
Not clear |
| Robert G Bennett, Frederick G Hamel, William C Duckwort. An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes. vol 52. issue 9. 2003-10-07. PMID:12941771. |
the ide inhibitor bacitracin inhibited amylin degradation by 78% and insulin degradation by 100%. |
2003-10-07 |
2023-08-12 |
human |
| Frankie B Stentz, Abbas E Kitabch. Activated T lymphocytes in Type 2 diabetes: implications from in vitro studies. Current drug targets. vol 4. issue 6. 2003-08-29. PMID:12866664. |
concomitant with the insulin receptors, two other growth factor receptors (igf-1 and il-2) also emerge on the t lymphocyte cell surface along with intracellular signal transduction mechanisms and insulin degrading enzyme (ide). |
2003-08-29 |
2023-08-12 |
human |
| R G Bennett, J Fawcett, M C Kruer, W C Duckworth, F G Hame. Insulin inhibition of the proteasome is dependent on degradation of insulin by insulin-degrading enzyme. The Journal of endocrinology. vol 177. issue 3. 2003-08-11. PMID:12773120. |
insulin inhibition of proteasomal activity requires interaction with insulin-degrading enzyme (ide), but it is unclear if proteasome inhibition is dependent merely on insulin-nide binding or if degradation of insulin by ide is required. |
2003-08-11 |
2023-08-12 |
Not clear |
| R G Bennett, J Fawcett, M C Kruer, W C Duckworth, F G Hame. Insulin inhibition of the proteasome is dependent on degradation of insulin by insulin-degrading enzyme. The Journal of endocrinology. vol 177. issue 3. 2003-08-11. PMID:12773120. |
to test the hypothesis that degradation by ide is required for proteasome inhibition, a panel of insulin analogues with variable susceptibility to degradation by ide binding was used to assess effects on the proteasome. |
2003-08-11 |
2023-08-12 |
Not clear |
| R G Bennett, J Fawcett, M C Kruer, W C Duckworth, F G Hame. Insulin inhibition of the proteasome is dependent on degradation of insulin by insulin-degrading enzyme. The Journal of endocrinology. vol 177. issue 3. 2003-08-11. PMID:12773120. |
in contrast, although insulin and lispro were readily degraded by ide, asp(b10) was degraded more slowly, and eqf degradation was undetectable. |
2003-08-11 |
2023-08-12 |
Not clear |
| R G Bennett, J Fawcett, M C Kruer, W C Duckworth, F G Hame. Insulin inhibition of the proteasome is dependent on degradation of insulin by insulin-degrading enzyme. The Journal of endocrinology. vol 177. issue 3. 2003-08-11. PMID:12773120. |
these data suggest that insulin inhibition of proteasome activity is dependent on degradation by ide. |
2003-08-11 |
2023-08-12 |
Not clear |
| R G Bennett, J Fawcett, M C Kruer, W C Duckworth, F G Hame. Insulin inhibition of the proteasome is dependent on degradation of insulin by insulin-degrading enzyme. The Journal of endocrinology. vol 177. issue 3. 2003-08-11. PMID:12773120. |
the mechanism of proteasome inhibition may be the generation of inhibitory fragments of insulin, or by displacement of ide from the proteasome. |
2003-08-11 |
2023-08-12 |
Not clear |
| S D Edland, F Wavrant-De Vriesé, D Compton, G E Smith, R Ivnik, B F Boeve, E G Tangalos, R C Peterse. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE). Neuroscience letters. vol 345. issue 1. 2003-07-10. PMID:12809979. |
insulin degrading enzyme (ide) genetic variants and risk of alzheimer's disease: evidence of effect modification by apolipoprotein e (apoe). |
2003-07-10 |
2023-08-12 |
human |
| S D Edland, F Wavrant-De Vriesé, D Compton, G E Smith, R Ivnik, B F Boeve, E G Tangalos, R C Peterse. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE). Neuroscience letters. vol 345. issue 1. 2003-07-10. PMID:12809979. |
insulin degrading enzyme (ide) is a protease that degrades insulin and the beta-amyloid peptide implicated in alzheimer's disease (ad). |
2003-07-10 |
2023-08-12 |
human |